

Oxybates (GHB) "off-label" for severe insomnia and other conditions
Other conditions that Google mentions:
• Fibromyalgia: Historically studied and prescribed off-label for managing widespread pain and improving restorative sleep in severe cases.
• Parkinson's Disease-Related Sleep Issues:
Used for managing severe sleep fragmentation or hypersomnia secondary to Parkinson's.
• Chronic Pain & Neuropathy: Sometimes utilized off-label to manage refractory neuropathic pain by modulating neurotransmitter activity.
• Alcohol Withdrawal: In some clinical research settings, oxybate formulations have been explored to manage severe alcohol withdrawal symptoms.
• Dystonia: Specifically in patients with alcohol-responsive dystonia and spasmodic dysphonia.
• Anxiety Disorders: There are exploratory studies on its effectiveness in reducing symptoms of severe anxiety.
• Treatment-Resistant Depression: It is sometimes considered for patients who have not responded to standard antidepressants, though it is not a first-line treatment.
When will, at least, this corruption on the price end? The conspiracy against this substance is forever? I never seen anything like it.
GOOGLE:
Between its initial FDA approval in 2002 and 2014, the list price for sodium oxybate (Xyrem) surged by 841%.
Key Price Milestones (Xyrem)
• 2007: The annual cost was roughly $11,169.
• 2014: The annual cost reached $106,215.
• Recent (2025/2026): The annual list price for brand-name Xyrem rose to over $182,000), although the entry of authorized generics in 2023 has dropped the retail price to roughly $5,200 for 180ml or about $10,000 per month without insurance.
Jazz Pharmaceuticals has recently resolved multiple high-profile antitrust and patent lawsuits. Most notably, they paid $145 million to resolve claims that they conspired with Hikma Pharmaceuticals to delay the launch of generic alternatives to their narcolepsy drug, Xyrem. They also reached a global settlement resolving multi-front litigation with Avadel Pharmaceuticals.